MedDataX Logo

Trial Outcomes & Findings for Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors (NCT NCT02709889)

NCT ID: NCT02709889

Last Updated: 2020-10-19

Results Overview

The number of participants with TEAEs, serious TEAEs, study drug-related TEAEs, and study drug discontinuations or dose reductions due to TEAEs, summarized by dose received and neuroendocrine (NEC) or non-NEC disease groups. An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: is fatal or life-threatening; results in death or hospitalization; is disabling/incapacitating or a congenital anomaly/birth defect; is medically significant. AE severity was graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03 terminology: grade 1=mild; grade 2=moderate; grade 3=severe; grade 4 life-threatening; grade 5=death. TEAEs were defined as AEs that were newly occurring or worsened following study treatment.

Recruitment status

TERMINATED

Study phase

PHASE1/PHASE2

Target enrollment

200 participants

Primary outcome timeframe

From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).

Results posted on

2020-10-19

Participant Flow

Participants were enrolled into a standard 3+3 dose-escalation study within disease-specific cohorts in Part A, and then participants were enrolled into a disease-specific expansion cohort in Part B based on the maximum tolerated dose determined in Part A.

Participant milestones

Participant milestones
Measure
Part A: Rovalpituzumab Tesirine 0.2 mg/kg
Participants who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Part A: Rovalpituzumab Tesirine 0.3 mg/kg
Participants who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Part A: Rovalpituzumab Tesirine 0.4 mg/kg
Participants who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Part B: Rovalpituzumab Tesirine 0.3 mg/kg
Participants who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Overall Study
STARTED
43
57
12
88
Overall Study
Large Cell Neuroendocrine Carcinoma(NEC)
3
4
2
4
Overall Study
Neuroendocrine Prostate Cancer
4
7
3
7
Overall Study
Gastroenteropancreatic NEC
6
5
2
23
Overall Study
Other NEC
11
12
1
7
Overall Study
Malignant Melanoma
3
6
0
11
Overall Study
Medullary Thyroid Cancer
3
3
0
7
Overall Study
Glioblastoma
4
4
1
14
Overall Study
Other Solid Tumors
9
16
3
15
Overall Study
COMPLETED
0
0
0
0
Overall Study
NOT COMPLETED
43
57
12
88

Reasons for withdrawal

Reasons for withdrawal
Measure
Part A: Rovalpituzumab Tesirine 0.2 mg/kg
Participants who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Part A: Rovalpituzumab Tesirine 0.3 mg/kg
Participants who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Part A: Rovalpituzumab Tesirine 0.4 mg/kg
Participants who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Part B: Rovalpituzumab Tesirine 0.3 mg/kg
Participants who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Overall Study
Withdrawal by Subject
11
10
2
12
Overall Study
Death
25
38
4
44
Overall Study
Physician Decision
1
2
3
5
Overall Study
Lost to Follow-up
2
0
0
4
Overall Study
Study Terminated by Sponsor
4
6
2
17
Overall Study
Other, Not Specified
0
1
1
6

Baseline Characteristics

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Large Cell Neuroendocrine Carcinoma
n=13 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Neuroendocrine Prostate Cancer
n=21 Participants
Participants with neuroendocrine prostate cancer (NEPC) who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Gastroenteropancreatic Neuroendocrine Carcinoma
n=36 Participants
Participants with high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Other Neuroendocrine Carcinoma
n=31 Participants
Participants with other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Malignant Melanoma
n=20 Participants
Participants with malignant melanoma (MM) who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Medullary Thyroid Cancer
n=13 Participants
Participants with medullary thyroid cancer (MTC) who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Glioblastoma
n=23 Participants
Participants with glioblastoma (GBM) who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Other Solid Tumors
n=43 Participants
Participants with other solid tumors who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Total
n=200 Participants
Total of all reporting groups
Age, Customized
< 65 years old
7 Participants
n=5 Participants
7 Participants
n=7 Participants
25 Participants
n=5 Participants
19 Participants
n=4 Participants
11 Participants
n=21 Participants
11 Participants
n=10 Participants
17 Participants
n=115 Participants
23 Participants
n=6 Participants
120 Participants
n=6 Participants
Age, Customized
>= 65 years old
6 Participants
n=5 Participants
14 Participants
n=7 Participants
11 Participants
n=5 Participants
12 Participants
n=4 Participants
9 Participants
n=21 Participants
2 Participants
n=10 Participants
6 Participants
n=115 Participants
20 Participants
n=6 Participants
80 Participants
n=6 Participants
Sex: Female, Male
Female
5 Participants
n=5 Participants
0 Participants
n=7 Participants
13 Participants
n=5 Participants
17 Participants
n=4 Participants
10 Participants
n=21 Participants
5 Participants
n=10 Participants
4 Participants
n=115 Participants
20 Participants
n=6 Participants
74 Participants
n=6 Participants
Sex: Female, Male
Male
8 Participants
n=5 Participants
21 Participants
n=7 Participants
23 Participants
n=5 Participants
14 Participants
n=4 Participants
10 Participants
n=21 Participants
8 Participants
n=10 Participants
19 Participants
n=115 Participants
23 Participants
n=6 Participants
126 Participants
n=6 Participants
Race/Ethnicity, Customized
White
11 Participants
n=5 Participants
17 Participants
n=7 Participants
32 Participants
n=5 Participants
25 Participants
n=4 Participants
20 Participants
n=21 Participants
10 Participants
n=10 Participants
20 Participants
n=115 Participants
40 Participants
n=6 Participants
175 Participants
n=6 Participants
Race/Ethnicity, Customized
Black or African American
0 Participants
n=5 Participants
3 Participants
n=7 Participants
3 Participants
n=5 Participants
2 Participants
n=4 Participants
0 Participants
n=21 Participants
0 Participants
n=10 Participants
0 Participants
n=115 Participants
1 Participants
n=6 Participants
9 Participants
n=6 Participants
Race/Ethnicity, Customized
Asian
2 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
2 Participants
n=4 Participants
0 Participants
n=21 Participants
1 Participants
n=10 Participants
1 Participants
n=115 Participants
0 Participants
n=6 Participants
7 Participants
n=6 Participants
Race/Ethnicity, Customized
Other, Not Specified
0 Participants
n=5 Participants
1 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
0 Participants
n=21 Participants
1 Participants
n=10 Participants
0 Participants
n=115 Participants
1 Participants
n=6 Participants
3 Participants
n=6 Participants
Race/Ethnicity, Customized
Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
2 Participants
n=4 Participants
0 Participants
n=21 Participants
1 Participants
n=10 Participants
2 Participants
n=115 Participants
1 Participants
n=6 Participants
6 Participants
n=6 Participants

PRIMARY outcome

Timeframe: From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).

Population: Safety Analysis Set: participants who received any amount of study drug. Presented by NEC/Non-NEC groups, inclusive of participants in parts A and B.

The number of participants with TEAEs, serious TEAEs, study drug-related TEAEs, and study drug discontinuations or dose reductions due to TEAEs, summarized by dose received and neuroendocrine (NEC) or non-NEC disease groups. An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: is fatal or life-threatening; results in death or hospitalization; is disabling/incapacitating or a congenital anomaly/birth defect; is medically significant. AE severity was graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03 terminology: grade 1=mild; grade 2=moderate; grade 3=severe; grade 4 life-threatening; grade 5=death. TEAEs were defined as AEs that were newly occurring or worsened following study treatment.

Outcome measures

Outcome measures
Measure
NEC: 0.2 mg/kg
n=24 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.3 mg/kg
n=69 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.4 mg/kg
n=8 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: Any Dose
n=101 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.2 mg/kg
n=19 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.3 mg/kg
n=76 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.4 mg/kg
n=4 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: Any Dose
n=99 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 DR TEAE Leading to Study Drug DC, Grade 3-4
2 participants
7 participants
1 participants
10 participants
2 participants
4 participants
2 participants
8 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 TEAE Leading to Dose Reduction, Grade 3-4
0 participants
5 participants
1 participants
6 participants
0 participants
4 participants
0 participants
4 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 TEAE Leading to Dose Reduction, Grade 5
0 participants
0 participants
0 participants
0 participants
0 participants
0 participants
0 participants
0 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥1 TEAE Leading to Study Drug Discontinuation (DC)
4 participants
15 participants
5 participants
24 participants
5 participants
10 participants
2 participants
14 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 TEAE Leading to Study Drug DC, Grade 3-4
2 participants
11 participants
2 participants
15 participants
4 participants
4 participants
2 participants
8 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 TEAE
24 participants
69 participants
8 participants
101 participants
18 participants
75 participants
4 participants
97 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 TEAE, Grade 3-4
20 participants
40 participants
5 participants
65 participants
10 participants
38 participants
4 participants
52 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 TEAE, Grade 5
1 participants
13 participants
2 participants
16 participants
3 participants
8 participants
0 participants
11 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 Serious TEAE
16 participants
39 participants
5 participants
60 participants
10 participants
38 participants
3 participants
51 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 Serious TEAE, Grade 3-4
16 participants
24 participants
3 participants
43 participants
6 participants
25 participants
3 participants
34 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 Serious TEAE, Grade 5
0 participants
13 participants
2 participants
15 participants
3 participants
8 participants
0 participants
11 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 Drug-Related (DR) Serious TEAE
6 participants
20 participants
3 participants
29 participants
3 participants
14 participants
3 participants
20 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 DR Serious TEAE, Grade 3-4
6 participants
15 participants
1 participants
22 participants
3 participants
8 participants
3 participants
14 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 DR Serious TEAE, Grade 5
0 participants
2 participants
2 participants
4 participants
0 participants
2 participants
0 participants
2 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 DR TEAE
21 participants
64 participants
8 participants
93 participants
16 participants
68 participants
4 participants
88 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥1 TEAE Leading to Study Drug DC, Grade 5
0 participants
1 participants
2 participants
3 participants
1 participants
2 participants
0 participants
2 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 DR TEAE, Grade 3-4
14 participants
43 participants
3 participants
60 participants
6 participants
27 participants
4 participants
37 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 DR TEAE, Grade 5
0 participants
2 participants
2 participants
4 participants
0 participants
2 participants
0 participants
2 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 DR TEAE Leading to Study Drug DC
4 participants
10 participants
4 participants
18 participants
2 participants
10 participants
2 participants
14 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 DR TEAE Leading to Study Drug DC, Grade 5
0 participants
1 participants
2 participants
3 participants
0 participants
2 participants
0 participants
2 participants
Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups
≥ 1 TEAE Leading to Dose Reduction
0 participants
7 participants
2 participants
9 participants
0 participants
7 participants
0 participants
7 participants

SECONDARY outcome

Timeframe: Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 35.2 months.

Population: Full Analysis Set: All enrolled participants who received any amount of study drug. Presented by disease-specific groups, inclusive of participants in parts A and B.

ORR is defined as percentage of participants whose best overall response was either complete response (CR) or partial response (PR), according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Outcome measures

Outcome measures
Measure
NEC: 0.2 mg/kg
n=13 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.3 mg/kg
n=21 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.4 mg/kg
n=36 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: Any Dose
n=31 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.2 mg/kg
n=20 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.3 mg/kg
n=13 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.4 mg/kg
n=23 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: Any Dose
n=43 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Objective Response Rate (ORR)
7.7 percentage of participants
Interval 0.2 to 36.0
4.8 percentage of participants
Interval 0.1 to 23.8
13.9 percentage of participants
Interval 4.7 to 29.5
22.6 percentage of participants
Interval 9.6 to 41.1
10.0 percentage of participants
Interval 1.2 to 31.7
15.4 percentage of participants
Interval 1.9 to 45.4
4.3 percentage of participants
Interval 0.1 to 21.9
4.7 percentage of participants
Interval 0.6 to 15.8

SECONDARY outcome

Timeframe: Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 35.2 months.

Population: Full Analysis Set: All enrolled participants who received any amount of study drug. Presented by disease-specific groups, inclusive of participants in parts A and B.

CBR is defined as the percentage of participants with best overall response (confirmed or unconfirmed) of CR, PR or stable disease (SD) per RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressed disease (PD), taking as reference the smallest sum diameters while on study. SD criteria must have met at least once after study entry at a minimum interval of 42 days (-7 days to allow for scheduled visit window per the protocol).

Outcome measures

Outcome measures
Measure
NEC: 0.2 mg/kg
n=13 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.3 mg/kg
n=21 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.4 mg/kg
n=36 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: Any Dose
n=31 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.2 mg/kg
n=20 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.3 mg/kg
n=13 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.4 mg/kg
n=23 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: Any Dose
n=43 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Clinical Benefit Rate (CBR)
76.9 percentage of participants
Interval 46.2 to 95.0
76.2 percentage of participants
Interval 52.8 to 91.8
63.9 percentage of participants
Interval 46.2 to 79.2
61.3 percentage of participants
Interval 42.2 to 78.2
60.0 percentage of participants
Interval 36.1 to 80.9
76.9 percentage of participants
Interval 46.2 to 95.0
30.4 percentage of participants
Interval 13.2 to 52.9
46.5 percentage of participants
Interval 31.2 to 62.3

SECONDARY outcome

Timeframe: Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 35.2 months.

Population: Full Analysis Set: All enrolled participants who received any amount of study drug. Responders (CR or PR response). Presented by disease-specific groups, inclusive of participants in parts A and B.

DOR is defined as the time from the first assessment on therapy of a CR or PR response (per RECIST v1.1) to the date of progressive disease or death. CR: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: A ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants who did not have progression were censored at the last non-missing response assessment on-therapy or baseline. Based on Kaplan-Meier estimates.

Outcome measures

Outcome measures
Measure
NEC: 0.2 mg/kg
n=2 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.3 mg/kg
n=4 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.4 mg/kg
n=9 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: Any Dose
n=8 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.2 mg/kg
n=3 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.3 mg/kg
n=2 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.4 mg/kg
n=1 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: Any Dose
n=3 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Duration of Response (DOR)
NA months
NA=Not Estimable. Statistic could not be estimated due to an insufficient number of participants with progressive disease.
3.0 months
Interval 2.8 to 3.1
2.6 months
Interval 0.5 to 3.7
6.7 months
Interval 2.0 to
NA=Not Estimable. Statistic could not be estimated due to an insufficient number of participants with progressive disease.
NA months
Interval 2.9 to
NA=Not Estimable. Statistic could not be estimated due to an insufficient number of participants with progressive disease.
NA months
Interval 4.5 to
NA=Not Estimable. Statistic could not be estimated due to an insufficient number of participants with progressive disease.
4.6 months
1 participant analyzed
3.9 months
Interval 0.4 to 4.1

SECONDARY outcome

Timeframe: Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 35.2 months.

Population: Full Analysis Set: All enrolled participants who received any amount of study drug. Presented by disease-specific groups, inclusive of participants in parts A and B.

PFS is defined as the time from the first dose date to the date of disease progression or death. Participants who did not have progression or death are censored at the last non-missing response assessment on-therapy or baseline. Based on Kaplan-Meier estimates.

Outcome measures

Outcome measures
Measure
NEC: 0.2 mg/kg
n=13 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.3 mg/kg
n=21 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.4 mg/kg
n=36 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: Any Dose
n=31 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.2 mg/kg
n=20 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.3 mg/kg
n=13 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.4 mg/kg
n=23 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: Any Dose
n=43 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Progression Free Survival (PFS)
4.6 months
Interval 1.2 to
NA=Not Estimable. Statistic could not be estimated due to an insufficient number of participants with progressive disease.
4.5 months
Interval 2.5 to 5.7
3.3 months
Interval 2.3 to 5.0
3.1 months
Interval 1.3 to 6.0
2.9 months
Interval 1.3 to 3.7
11.7 months
Interval 1.3 to
NA=Not Estimable. Statistic could not be estimated due to an insufficient number of participants with progressive disease.
1.4 months
Interval 1.3 to 2.5
2.1 months
Interval 1.3 to 3.3

SECONDARY outcome

Timeframe: Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 35.2 months.

Population: Full Analysis Set: All enrolled participants who received any amount of study drug. Presented by disease-specific groups, inclusive of participants in parts A and B.

Overall survival is defined as the time from the first dose date to death for any reason. Subjects who were alive at the clinical data cut-off are censored at the last known alive date. Based on Kaplan-Meier estimates.

Outcome measures

Outcome measures
Measure
NEC: 0.2 mg/kg
n=13 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.3 mg/kg
n=21 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.4 mg/kg
n=36 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: Any Dose
n=31 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.2 mg/kg
n=20 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.3 mg/kg
n=13 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.4 mg/kg
n=23 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: Any Dose
n=43 Participants
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Overall Survival (OS)
7.7 months
Interval 2.4 to
NA=Not Estimable. Statistic could not be estimated due to an insufficient number of participants with progressive disease.
5.7 months
Interval 2.7 to 7.3
6.7 months
Interval 3.9 to 9.7
6.6 months
Interval 4.3 to 12.2
7.5 months
Interval 3.6 to 9.2
NA months
Interval 6.0 to
NA=Not Estimable. Statistic could not be estimated due to an insufficient number of participants with progressive disease.
6.6 months
Interval 3.7 to 7.4
5.5 months
Interval 4.2 to 6.0

SECONDARY outcome

Timeframe: Cycle 1: 0, 0.5, 6, 48, 168, 336, 672 hours postdose

Population: Participants who received at least 1 dose of study drug and had an assessment at given time point. Presented by dose-specific groups, inclusive of participants in parts A and B.

Outcome measures

Outcome measures
Measure
NEC: 0.2 mg/kg
n=43 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.3 mg/kg
n=139 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.4 mg/kg
n=12 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: Any Dose
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.2 mg/kg
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.3 mg/kg
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.4 mg/kg
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: Any Dose
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Serum Concentrations of Rovalpituzumab Tesirine Over Time
Cycle 1: 0 hour
0.057 ug/mL
Standard Deviation 0.367
0.044 ug/mL
Standard Deviation 0.507
0 ug/mL
Standard Deviation 0
—
—
—
—
—
Serum Concentrations of Rovalpituzumab Tesirine Over Time
Cycle 1: 0.5 hour postdose
4.799 ug/mL
Standard Deviation 1.474
7.351 ug/mL
Standard Deviation 2.640
10.785 ug/mL
Standard Deviation 1.516
—
—
—
—
—
Serum Concentrations of Rovalpituzumab Tesirine Over Time
Cycle 1: 6 hours postdose
4.377 ug/mL
Standard Deviation 1.222
6.710 ug/mL
Standard Deviation 1.701
9.355 ug/mL
Standard Deviation 0.859
—
—
—
—
—
Serum Concentrations of Rovalpituzumab Tesirine Over Time
Cycle 1: 48 hours postdose
2.760 ug/mL
Standard Deviation 0.939
4.483 ug/mL
Standard Deviation 1.317
6.049 ug/mL
Standard Deviation 1.171
—
—
—
—
—
Serum Concentrations of Rovalpituzumab Tesirine Over Time
Cycle 1: 168 hours postdose
1.494 ug/mL
Standard Deviation 0.569
2.392 ug/mL
Standard Deviation 0.902
3.250 ug/mL
Standard Deviation 0.825
—
—
—
—
—
Serum Concentrations of Rovalpituzumab Tesirine Over Time
Cycle 1: 336 hours postdose
0.963 ug/mL
Standard Deviation 0.470
1.633 ug/mL
Standard Deviation 0.710
2.302 ug/mL
Standard Deviation 0.703
—
—
—
—
—
Serum Concentrations of Rovalpituzumab Tesirine Over Time
Cycle 1: 672 hours postdose
0.515 ug/mL
Standard Deviation 0.278
0.976 ug/mL
Standard Deviation 0.410
1.272 ug/mL
Standard Deviation 0.414
—
—
—
—
—

SECONDARY outcome

Timeframe: Day 1 and 42 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).

Population: Participants who received at least 1 dose of study drug with available ATA data. Presented by dose-specific groups, inclusive of participants in parts A and B.

Number of participants treated across each dose level reported to potentially have ATAs against rovalpituzumab tesirine at any time during the study.

Outcome measures

Outcome measures
Measure
NEC: 0.2 mg/kg
n=42 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.3 mg/kg
n=145 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: 0.4 mg/kg
n=12 Participants
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
NEC: Any Dose
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin, neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.2 mg/kg
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.3 mg/kg
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: 0.4 mg/kg
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Non-NEC: Any Dose
Participants with malignant melanoma (MM), medullary thyroid cancer (MTC), glioblastoma (GBM), or other solid tumors who received rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Number of Participants With Anti-therapeutic Antibodies (ATA)
5 participants
10 participants
1 participants
—
—
—
—
—

Adverse Events

0.2_mg_kg_(LCNEC)

Serious events: 2 serious events
Other events: 3 other events
Deaths: 1 deaths

0.2_mg_kg_(NEPC)

Serious events: 3 serious events
Other events: 4 other events
Deaths: 3 deaths

0.2_mg_kg_(GEPNEC)

Serious events: 2 serious events
Other events: 6 other events
Deaths: 5 deaths

0.2_mg_kg_(Other_NEC)

Serious events: 9 serious events
Other events: 11 other events
Deaths: 9 deaths

0.2_mg_kg_(MM)

Serious events: 2 serious events
Other events: 3 other events
Deaths: 3 deaths

0.2_mg_kg_(MTC)

Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths

0.2_mg_kg_(GBM)

Serious events: 2 serious events
Other events: 4 other events
Deaths: 4 deaths

0.2_mg_kg_(Other_Solid)

Serious events: 5 serious events
Other events: 8 other events
Deaths: 6 deaths

0.3_mg_kg_(LCNEC)

Serious events: 6 serious events
Other events: 8 other events
Deaths: 6 deaths

0.3_mg_kg_(NEPC)

Serious events: 8 serious events
Other events: 14 other events
Deaths: 11 deaths

0.3_mg_kg_(GEPNEC)

Serious events: 15 serious events
Other events: 27 other events
Deaths: 16 deaths

0.3_mg_kg_(Other_NEC)

Serious events: 10 serious events
Other events: 19 other events
Deaths: 12 deaths

0.3_mg_kg_(MM)

Serious events: 8 serious events
Other events: 16 other events
Deaths: 10 deaths

0.3_mg_kg_(MTC)

Serious events: 3 serious events
Other events: 10 other events
Deaths: 3 deaths

0.3_mg_kg_(GBM)

Serious events: 8 serious events
Other events: 18 other events
Deaths: 13 deaths

0.3_mg_kg_(Other_Solid)

Serious events: 19 serious events
Other events: 31 other events
Deaths: 25 deaths

0.4_mg_kg_(GBM)

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

0.4_mg_kg_(GEPNEC)

Serious events: 2 serious events
Other events: 2 other events
Deaths: 2 deaths

0.4_mg_kg_(LCNEC)

Serious events: 1 serious events
Other events: 2 other events
Deaths: 0 deaths

0.4_mg_kg_(NEPC)

Serious events: 2 serious events
Other events: 3 other events
Deaths: 2 deaths

0.4_mg_kg_(Other_NEC)

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

0.4_mg_kg_(Other_Solid)

Serious events: 3 serious events
Other events: 3 other events
Deaths: 2 deaths

Serious adverse events

Serious adverse events
Measure
0.2_mg_kg_(LCNEC)
n=3 participants at risk
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(NEPC)
n=4 participants at risk
Participants with neuroendocrine prostate cancer (NEPC) who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(GEPNEC)
n=6 participants at risk
Participants with high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(Other_NEC)
n=11 participants at risk
Participants with other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(MM)
n=3 participants at risk
Participants with malignant melanoma (MM) who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(MTC)
n=3 participants at risk
Participants with medullary thyroid cancer (MTC) who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(GBM)
n=4 participants at risk
Participants with glioblastoma (GBM) who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(Other_Solid)
n=9 participants at risk
Participants with other solid tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(LCNEC)
n=8 participants at risk
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(NEPC)
n=14 participants at risk
Participants with neuroendocrine prostate cancer (NEPC) who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(GEPNEC)
n=28 participants at risk
Participants with high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(Other_NEC)
n=19 participants at risk
Participants with other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(MM)
n=17 participants at risk
Participants with malignant melanoma (MM) who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(MTC)
n=10 participants at risk
Participants with medullary thyroid cancer (MTC) who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(GBM)
n=18 participants at risk
Participants with glioblastoma (GBM) who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(Other_Solid)
n=31 participants at risk
Participants with other solid tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.4_mg_kg_(GBM)
n=1 participants at risk
Participants with glioblastoma (GBM) who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.4_mg_kg_(GEPNEC)
n=2 participants at risk
Participants with high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.4_mg_kg_(LCNEC)
n=2 participants at risk
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.4_mg_kg_(NEPC)
n=3 participants at risk
Participants with neuroendocrine prostate cancer (NEPC) who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.4_mg_kg_(Other_NEC)
n=1 participants at risk
Participants with other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.4_mg_kg_(Other_Solid)
n=3 participants at risk
Participants with other solid tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
Infections and infestations
Rash pustular
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Sepsis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Urinary tract infection
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Sepsis syndrome
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Urosepsis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Injury, poisoning and procedural complications
Postoperative wound complication
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Blood and lymphatic system disorders
Anaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Blood and lymphatic system disorders
Pancytopenia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Blood and lymphatic system disorders
Thrombocytopenia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Pyrexia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Atrial fibrillation
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Atrial flutter
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Pericardial effusion
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Supraventricular tachycardia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Tachycardia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Abdominal distension
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Abdominal pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Ascites
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Constipation
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Diarrhoea
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Duodenitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Gastrointestinal haemorrhage
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Intestinal obstruction
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Nausea
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Pancreatitis acute
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Small intestinal obstruction
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Vomiting
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Fatigue
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Gait disturbance
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Generalised oedema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Infusion site extravasation
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Multiple organ dysfunction syndrome
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Oedema peripheral
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Hepatobiliary disorders
Bile duct obstruction
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Hepatobiliary disorders
Cholangitis acute
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Hepatobiliary disorders
Cholecystitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Hepatobiliary disorders
Cholecystitis acute
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Hepatobiliary disorders
Hepatic failure
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Hepatobiliary disorders
Hepatotoxicity
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Hepatobiliary disorders
Hyperbilirubinaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Hepatobiliary disorders
Liver injury
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Abdominal abscess
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Bacteraemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Cellulitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Clostridial sepsis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Corona virus infection
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Device related infection
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Diverticulitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Escherichia bacteraemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Pneumonia
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Confusional state
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Injury, poisoning and procedural complications
Subdural haematoma
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Blood bilirubin increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Liver function test increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Transaminases increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Troponin increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Dehydration
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.9%
4/31 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Failure to thrive
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Fluid overload
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypercalcaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hyperglycaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypervolaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypokalaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hyponatraemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Tumour lysis syndrome
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Arthralgia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Back pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Bone pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Flank pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Pain in extremity
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Pathological fracture
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm progression
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
2/14 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
7/28 • Number of events 7 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
3/18 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm malignant
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Brain oedema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Cerebral haemorrhage
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Cerebral infarction
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Hepatic encephalopathy
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Seizure
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Toxic encephalopathy
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Delirium
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Mental status changes
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Acute kidney injury
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Hydronephrosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Renal impairment
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Renal injury
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Dyspnoea
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Epistaxis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Pleural effusion
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
27.3%
3/11 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.6%
1/28 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Vascular disorders
Deep vein thrombosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Pneumonitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Vascular disorders
Embolism
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
3.2%
1/31 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Respiratory failure
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Rash maculo-papular
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Vascular disorders
Hypotension
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Vascular disorders
Jugular vein thrombosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Vascular disorders
Subclavian artery thrombosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.

Other adverse events

Other adverse events
Measure
0.2_mg_kg_(LCNEC)
n=3 participants at risk
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(NEPC)
n=4 participants at risk
Participants with neuroendocrine prostate cancer (NEPC) who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(GEPNEC)
n=6 participants at risk
Participants with high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(Other_NEC)
n=11 participants at risk
Participants with other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(MM)
n=3 participants at risk
Participants with malignant melanoma (MM) who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(MTC)
n=3 participants at risk
Participants with medullary thyroid cancer (MTC) who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(GBM)
n=4 participants at risk
Participants with glioblastoma (GBM) who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.2_mg_kg_(Other_Solid)
n=9 participants at risk
Participants with other solid tumors who received rovalpituzumab tesirine 0.2 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(LCNEC)
n=8 participants at risk
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(NEPC)
n=14 participants at risk
Participants with neuroendocrine prostate cancer (NEPC) who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(GEPNEC)
n=28 participants at risk
Participants with high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(Other_NEC)
n=19 participants at risk
Participants with other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(MM)
n=17 participants at risk
Participants with malignant melanoma (MM) who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(MTC)
n=10 participants at risk
Participants with medullary thyroid cancer (MTC) who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(GBM)
n=18 participants at risk
Participants with glioblastoma (GBM) who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.3_mg_kg_(Other_Solid)
n=31 participants at risk
Participants with other solid tumors who received rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.4_mg_kg_(GBM)
n=1 participants at risk
Participants with glioblastoma (GBM) who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.4_mg_kg_(GEPNEC)
n=2 participants at risk
Participants with high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.4_mg_kg_(LCNEC)
n=2 participants at risk
Participants with large cell neuroendocrine carcinoma (LCNEC) of any origin who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.4_mg_kg_(NEPC)
n=3 participants at risk
Participants with neuroendocrine prostate cancer (NEPC) who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.4_mg_kg_(Other_NEC)
n=1 participants at risk
Participants with other neuroendocrine carcinoma (NEC), and high-grade neuroendocrine tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
0.4_mg_kg_(Other_Solid)
n=3 participants at risk
Participants with other solid tumors who received rovalpituzumab tesirine 0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
General disorders
Pyrexia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
4/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
15.8%
3/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.9%
4/31 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Confusional state
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Delusion
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Penile pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Peripheral swelling
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
2/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Pancreatitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Stomatitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Perineal pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Toothache
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Umbilical hernia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Conjunctival haemorrhage
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Blood and lymphatic system disorders
Anaemia
66.7%
2/3 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
36.4%
4/11 • Number of events 17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.7%
5/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.7%
10/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
31.6%
6/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
17.6%
3/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
45.2%
14/31 • Number of events 26 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
66.7%
2/3 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Blood and lymphatic system disorders
Hypercoagulation
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Blood and lymphatic system disorders
Leukocytosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Blood and lymphatic system disorders
Leukopenia
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.7%
3/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Blood and lymphatic system disorders
Lymphadenopathy
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Blood and lymphatic system disorders
Lymphopenia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Blood and lymphatic system disorders
Neutropenia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Blood and lymphatic system disorders
Normocytic anaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Blood and lymphatic system disorders
Thrombocytopenia
66.7%
2/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
45.5%
5/11 • Number of events 27 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
62.5%
5/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.7%
5/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
39.3%
11/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
42.1%
8/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
20.0%
2/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
3/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.5%
11/31 • Number of events 20 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
2/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
66.7%
2/3 • Number of events 6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Acute myocardial infarction
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Atrial fibrillation
33.3%
1/3 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Bradycardia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Cardiac failure congestive
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Palpitations
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Pericardial effusion
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
22.2%
2/9 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.7%
5/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
17.9%
5/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
26.3%
5/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
23.5%
4/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
30.0%
3/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
22.2%
4/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.9%
4/31 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Pericarditis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Sinus tachycardia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Cardiac disorders
Tachycardia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
15.8%
3/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Ear and labyrinth disorders
Ear congestion
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Ear and labyrinth disorders
Vertigo
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Endocrine disorders
Adrenal insufficiency
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Diplopia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Dry eye
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Eye irritation
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Eye pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Eye pruritus
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Eye swelling
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Ocular discomfort
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Orbital oedema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Periorbital oedema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Photophobia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Uveitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Vision blurred
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Eye disorders
Visual impairment
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Abdominal discomfort
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Abdominal pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
2/6 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
36.4%
4/11 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
22.2%
2/9 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
37.5%
3/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
28.6%
8/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
20.0%
2/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Abdominal pain lower
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
22.2%
2/9 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.1%
5/31 • Number of events 7 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Abdominal pain upper
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
22.2%
2/9 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
17.6%
3/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Abdominal tenderness
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Ascites
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
6/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
2/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Constipation
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
2/6 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
22.2%
2/9 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
37.5%
3/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
42.9%
6/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
4/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
26.3%
5/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
20.0%
2/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.1%
5/31 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Dental caries
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Diarrhoea
66.7%
2/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
2/6 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
66.7%
2/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
37.5%
3/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.7%
5/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
4/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
17.6%
3/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Dry mouth
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
2/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Dyspepsia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Dysphagia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Enteritis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Epigastric discomfort
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Eructation
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Flatulence
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Gastritis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Haemorrhoids
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Gastrointestinal inflammation
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Gastrooesophageal reflux disease
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
20.0%
2/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Haematochezia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Haemorrhoidal haemorrhage
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Vomiting
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
3/6 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
36.4%
4/11 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
3/9 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
37.5%
3/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
28.6%
4/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.7%
3/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.1%
4/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
17.6%
3/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
6/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
19.4%
6/31 • Number of events 7 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Lip dry
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Lip haemorrhage
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Lip swelling
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Malabsorption
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Nausea
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
2/6 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
45.5%
5/11 • Number of events 6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
3/3 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
4/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
42.9%
6/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
32.1%
9/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
47.4%
9/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
29.4%
5/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
30.0%
3/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
22.2%
4/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
32.3%
10/31 • Number of events 10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Oesophageal spasm
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Oral pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Pancreatic failure
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hyperammonaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hyperamylasaemia
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypercalcaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypercholesterolaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hyperglycaemia
33.3%
1/3 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hyperkalaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hyperlipasaemia
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
2/6 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hyperlipidaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypermagnesaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypernatraemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypoalbuminaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
36.4%
4/11 • Number of events 6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
37.5%
3/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
6/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.1%
5/31 • Number of events 7 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypocalcaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypoglycaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypokalaemia
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
45.5%
5/11 • Number of events 9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
4/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.7%
3/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
19.4%
6/31 • Number of events 11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypomagnesaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hyponatraemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
2/4 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.7%
3/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Hypophosphataemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
27.3%
3/11 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Vitamin B6 deficiency
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Arthralgia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
2/4 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
27.3%
3/11 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
17.9%
5/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.1%
5/31 • Number of events 7 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Back pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
2/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.7%
3/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
19.4%
6/31 • Number of events 6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Flank pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Groin pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Haemarthrosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Hypercreatinaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Joint effusion
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Joint range of motion decreased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Joint swelling
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Limb discomfort
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Muscle spasms
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Muscular weakness
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
2/4 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Myalgia
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.7%
3/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
17.6%
3/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
20.0%
2/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Neck pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Osteoarthritis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Pain in extremity
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Pain in jaw
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Plantar fasciitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Spinal column stenosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Musculoskeletal and connective tissue disorders
Tendonitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm progression
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Aphasia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Asterixis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Ataxia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Brain oedema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Cerebral haematoma
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Disturbance in attention
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Dizziness
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
27.3%
3/11 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.7%
5/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
4/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Dizziness postural
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Dysaesthesia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Dysgeusia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
37.5%
3/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Encephalopathy
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Head discomfort
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Headache
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
27.3%
3/11 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
15.8%
3/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
20.0%
2/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Hemiparesis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Hydrocephalus
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Hypersomnia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Hypoaesthesia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Lethargy
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Mental impairment
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Metabolic encephalopathy
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Migraine
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Neuropathy peripheral
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Paraesthesia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Peripheral sensory neuropathy
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Somnolence
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
30.0%
3/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Spinal cord compression
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Syncope
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Nervous system disorders
Tremor
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Product Issues
Device occlusion
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Agitation
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Anxiety
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Compulsions
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Depressed mood
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Depression
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Hallucination
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Insomnia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
66.7%
2/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
22.2%
2/9 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
15.8%
3/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
66.7%
2/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Irritability
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Major depression
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Psychiatric disorders
Sleep disorder
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Acute kidney injury
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Bladder spasm
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Chronic kidney disease
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Dysuria
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Glycosuria
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Haematuria
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Micturition urgency
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Nephrolithiasis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Nocturia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Pollakiuria
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Polyuria
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Proteinuria
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Renal vein thrombosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Urinary incontinence
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Urinary retention
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Renal and urinary disorders
Urine flow decreased
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Female genital tract fistula
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Menorrhagia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Pelvic pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Scrotal erythema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Scrotal oedema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Scrotal pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Sexual dysfunction
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Vaginal haemorrhage
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Acquired diaphragmatic eventration
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Asthma
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Atelectasis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Gastrointestinal disorders
Abdominal distension
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
28.6%
4/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
7/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Asthenia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
28.6%
4/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.1%
5/31 • Number of events 8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Catheter site pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Catheter site vesicles
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Chest discomfort
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Chest pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Chills
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Early satiety
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Effusion
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Face oedema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Facial pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Fatigue
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
3/6 • Number of events 6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
45.5%
5/11 • Number of events 7 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
3/3 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
75.0%
3/4 • Number of events 9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
55.6%
5/9 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
87.5%
7/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
57.1%
8/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
52.6%
10/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
52.9%
9/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
40.0%
4/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
55.6%
10/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
41.9%
13/31 • Number of events 18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
2/2 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Feeling of body temperature change
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
14/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Gait disturbance
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
2/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Generalised oedema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Hernia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Influenza like illness
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Infusion site erythema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Injection site reaction
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Localised oedema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Mass
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Non-cardiac chest pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Oedema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Oedema peripheral
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
54.5%
6/11 • Number of events 13 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
22.2%
2/9 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
62.5%
5/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
7/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
7/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
15.8%
3/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
29.4%
5/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
30.0%
3/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
3/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
29.0%
9/31 • Number of events 13 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
General disorders
Tenderness
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Injury, poisoning and procedural complications
Infusion related reaction
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Hepatobiliary disorders
Hyperbilirubinaemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
32.1%
9/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
20.0%
2/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Hepatobiliary disorders
Jaundice
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Hepatobiliary disorders
Ocular icterus
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Hepatobiliary disorders
Portal fibrosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Immune system disorders
Immunodeficiency
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Abscess
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Bronchitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Cellulitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Conjunctivitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Cystitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Escherichia bacteraemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Fungal skin infection
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Klebsiella bacteraemia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Nasopharyngitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Oral candidiasis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Oral herpes
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Paronychia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Perineal cellulitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Pneumonia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Purulent discharge
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Rhinitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Sinusitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Subcutaneous abscess
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Tooth infection
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Upper respiratory tract infection
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Urinary tract infection
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.1%
4/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.9%
4/31 • Number of events 6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Infections and infestations
Vulvovaginal mycotic infection
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Injury, poisoning and procedural complications
Arthropod bite
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Injury, poisoning and procedural complications
Contusion
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
27.3%
3/11 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Injury, poisoning and procedural complications
Eye contusion
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Injury, poisoning and procedural complications
Fall
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
2/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Injury, poisoning and procedural complications
Procedural pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Injury, poisoning and procedural complications
Sunburn
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Injury, poisoning and procedural complications
Tooth fracture
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Injury, poisoning and procedural complications
Traumatic haematoma
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Alanine aminotransferase increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
66.7%
2/3 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
37.5%
3/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
2/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.7%
10/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
30.0%
3/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
3/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Amylase increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Aspartate aminotransferase increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
27.3%
3/11 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
3/3 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.7%
10/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.1%
4/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
20.0%
2/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
3/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.1%
5/31 • Number of events 11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
3/3 • Number of events 7 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Bilirubin conjugated increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Blood alkaline phosphatase increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
36.4%
4/11 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
2/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
28.6%
8/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
2/2 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
66.7%
2/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Blood bilirubin increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Blood creatinine increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Blood lactate dehydrogenase increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Blood lactic acid increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Electrocardiogram QT prolonged
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Gamma-glutamyltransferase increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Glomerular filtration rate decreased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Heart rate increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
International normalised ratio increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Prothrombin time prolonged
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Decreased appetite
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
2/6 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
36.4%
4/11 • Number of events 6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
66.7%
2/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
22.2%
2/9 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
37.5%
3/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
71.4%
10/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
17.9%
5/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.1%
4/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.3%
6/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
3/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.5%
11/31 • Number of events 11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
2/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Troponin I increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Weight decreased
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
66.7%
2/3 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Investigations
Weight increased
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
2/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Acidosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Cachexia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Dehydration
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.7%
3/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Diabetes mellitus
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Fluid intake reduced
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Metabolism and nutrition disorders
Fluid overload
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Lung infiltration
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Nasal congestion
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Pleural effusion
66.7%
2/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
2/6 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
75.0%
6/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
28.6%
4/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
28.6%
8/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
31.6%
6/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
23.5%
4/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
30.0%
3/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
27.8%
5/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.1%
5/31 • Number of events 8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
2/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
2/2 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Dyspnoea
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
62.5%
5/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.7%
5/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
17.9%
5/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
31.6%
6/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
23.5%
4/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
40.0%
4/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
3/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Cough
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
37.5%
3/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.7%
5/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
17.9%
5/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
17.6%
3/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
20.0%
2/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.9%
4/31 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Dry throat
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Dysphonia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Dyspnoea paroxysmal nocturnal
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Epistaxis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Reproductive system and breast disorders
Hiccups
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Hypoxia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Increased bronchial secretion
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Pneumonitis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Pneumothorax
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Productive cough
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Tachypnoea
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Upper respiratory tract congestion
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Respiratory, thoracic and mediastinal disorders
Wheezing
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Alopecia
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Blister
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Dermatitis acneiform
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Dry skin
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Ecchymosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Erythema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.7%
3/31 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Erythema multiforme
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Exfoliative rash
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Hyperhidrosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Nail bed disorder
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Nail discolouration
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Pain of skin
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Palmar erythema
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
1/1 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Petechiae
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Photosensitivity reaction
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
27.3%
3/11 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
100.0%
3/3 • Number of events 5 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
22.2%
2/9 • Number of events 3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
2/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
35.7%
10/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
29.4%
5/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
5/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
27.8%
5/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
19.4%
6/31 • Number of events 7 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Pigmentation disorder
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Pruritus
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
66.7%
2/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.5%
2/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Pruritus generalised
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Rash
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
27.3%
3/11 • Number of events 4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
20.0%
2/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Rash erythematous
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Rash macular
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
15.8%
3/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Rash maculo-papular
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
18.2%
2/11 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
2/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Rash papular
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.8%
2/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Rash pruritic
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Rash vesicular
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
14.3%
2/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Skin exfoliation
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Skin hyperpigmentation
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.0%
1/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Swelling face
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
1/9 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Skin and subcutaneous tissue disorders
Toxic erythema of chemotherapy
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
50.0%
1/2 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Vascular disorders
Capillary leak syndrome
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Vascular disorders
Deep vein thrombosis
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Vascular disorders
Flushing
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
1/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
7.1%
2/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Vascular disorders
Hot flush
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Vascular disorders
Hypertension
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
16.7%
1/6 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
9.1%
1/11 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
12.5%
1/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
10.7%
3/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.3%
1/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
11.1%
2/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Vascular disorders
Hypotension
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
25.0%
1/4 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
37.5%
3/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
21.4%
3/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
15.8%
3/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.9%
1/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
6.5%
2/31 • Number of events 2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
33.3%
1/3 • Number of events 1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
Vascular disorders
Thrombophlebitis superficial
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/6 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/11 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/4 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/9 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/8 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/14 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/28 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/19 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/17 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/10 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
5.6%
1/18 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/31 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/2 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/1 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.
0.00%
0/3 • From first dose of study drug through 30 days after last dose. The overall mean number of 6-week treatment cycles was 1 (range 1.0, 5.0).
No participants with malignant melanoma (MM) or medullary thyroid cancer (MTC) received the rovalpituzumab tesirine 0.4 mg/kg dose.

Additional Information

Global Medical Services

AbbVie

Phone: 800-633-9110

Results disclosure agreements

  • Principal investigator is a sponsor employee AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
  • Publication restrictions are in place

Restriction type: OTHER